MINNEAPOLIS - Aug. 25, 2014 - Medtronic, Inc. (MDT) today announced the U.S. Food and Drug Administration (FDA) approval of its newest cardiac resynchronization therapy-pacemaker, Viva® CRT-P, for ...

Upgrade to cardiac resynchronization therapy with a defibrillator (CRT-D) reduces morbidity and mortality and improves left ventricular (LV) reverse remodeling compared to an implantable ...

New York, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Cardiac Resynchronization Therapy Pacemaker Market Research ...

Please provide your email address to receive an email when new articles are posted on . A leadless pacemaker can deliver cardiac resynchronization therapy to patients who cannot have conventional CRT ...

Please provide your email address to receive an email when new articles are posted on . Long-term CRT-D use was tied to improved survival and time to adverse events vs. ICD therapy in patients with ...

New York, USA, Nov. 10, 2022 (GLOBE NEWSWIRE) -- The Global Cardiac Resynchronization Therapy Market is expected to Register an Immense Growth at a CAGR of 6.49% During the Forecast Period (2019–2027) ...

Doctors at Sentini Hospitals gave a new lease of life to a 62-year-old patient who suffered heart failure. In a press conference at the hospital on Wednesday, senior interventional cardiologist Dr.